Stand Up to Cancer
Researchers will explore combination treatment strategies with Mirati's adagrasib that can help patients overcome both primary and acquired resistance.
A research consortium in the Carolinas and Virginia is hoping to improve lung cancer prevention and personalized treatment in Black Americans.
Jazz Pharmaceuticals, SU2C Partner on Research on RAF Inhibitors, Pediatric Solid Cancer
The $4 million collaboration will focus on advancing research on Jazz's pan-RAF inhibitor JZP815, its approved agent Zepzelca, and clinical trial access disparities.
Mirati Therapeutics Donates $4M to Stand Up to Cancer to Advance KRAS-Mutant Cancer Treatment
The grant will support research efforts to target KRAS-mutated cancers with unmet need and develop tumor-agnostic approaches to treating KRAS-mutant cancers.
US, Canadian Researchers Partner to ID Biomarkers Predictive of Pancreatic Cancer Treatment
The project will involve molecular profiling of patients in a randomized trial and creating patient-derived organoids for personalized drug screening.